Inhalational versus total intravenous anesthesia in thoracoscopic-laparoscopic esophagectomy

注册号:

Registration number:

ITMCTR1900002352

最近更新日期:

Date of Last Refreshed on:

2019-05-23

注册时间:

Date of Registration:

2019-05-23

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

比较吸入麻醉和全凭静脉麻醉对腔镜食管切除术患者术后肺部并发症的影响

Public title:

Inhalational versus total intravenous anesthesia in thoracoscopic-laparoscopic esophagectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

比较吸入麻醉和全凭静脉麻醉对腔镜食管切除术患者术后肺部并发症的影响:前瞻性、随机、对照研究

Scientific title:

Inhalational versus total intravenous anesthesia in thoracoscopic-laparoscopic esophagectomy: a prospective randomized controlled trial

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900023336 ; ChiMCTR1900002352

申请注册联系人:

陈颖

研究负责人:

余海

Applicant:

Ying Chen

Study leader:

Hai Yu

申请注册联系人电话:

Applicant telephone:

+86 13980286158

研究负责人电话:

Study leader's telephone:

+86 18980601548

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yinfangyuan2009@163.com

研究负责人电子邮件:

Study leader's E-mail:

yuhaishan117@Yahoo.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

四川省西昌市建昌西路宁南干休所

研究负责人通讯地址:

中国四川省成都市武侯区国学巷37号

Applicant address:

Ningnan Cadres Recuperation Home, Jianchang Road West, Xichang, Sichuan

Study leader's address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

凉山州中西医结合医院

Applicant's institution:

Liangshan Prefecture Hospital of Integrated Traditional Chinese and Western Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2019年审(359)号

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

四川大学华西医院临床试验与生物医学伦理专委会

Name of the ethic committee:

The Medical Research Ethical Committee of the West China Hospital of Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2019/5/20 0:00:00

伦理委员会联系人:

左泽锦

Contact Name of the ethic committee:

Zhejin Zuo

伦理委员会联系地址:

中国四川省成都市武侯区国学巷37号

Contact Address of the ethic committee:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院

Primary sponsor:

West China Hospital, Sichuan University

研究实施负责(组长)单位地址:

中国四川省成都市武侯区国学巷37号

Primary sponsor's address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院

具体地址:

武侯区国学巷37号

Institution
hospital:

West China Hospital, Sichuan University

Address:

37 Guoxue Lane, Wuhou District

经费或物资来源:

Source(s) of funding:

none

研究疾病:

术后肺部并发症

研究疾病代码:

Target disease:

postoperative pulmonary complications

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

比较吸入麻醉和全凭静脉麻醉对腔镜食管切除术患者术后7天肺部并发症发生率的影响。

Objectives of Study:

Comparison of the effects of inhaled anesthesia and total intravenous anesthesia on the incidence of pulmonary complications at 7 days postoperatively in patients undergoing endoscopic esophagectomy.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.年龄>18岁; 2.ASA:I-III级; 3.全麻插管、择期行腔镜食管切除术; 4.签署知情同意书。

Inclusion criteria

1. Aged above 18 years; 2. ASA: Level I-III; 3. General anesthesia, elective laparoscopic esophagectomy; 4. Signing informed consent.

排除标准:

1. 任何原因不能配合研究或研究者认为不宜纳入本试验; 2. 既往对吸入麻醉药或丙泊酚过敏,或有恶性高热家族史; 3. 术前3月内急性肺损伤或急性呼吸窘迫综合征病史; 4. 合并心功能不全(NYHA心功能分级≥3级)、既往脑梗史、严重肝脏疾病(如肝脏衰竭)或慢性肾衰竭(肾小球滤过率<30ml/min )者; 5. 孕期、哺乳期女性; 6. 再次手术; 7. 参与其他临床试验。

Exclusion criteria:

1. Any reason cannot be combined with the research or the researcher believes that it is not suitable for inclusion in this experiment. 2. Previously allergic to inhaled anesthetics or propofol, or a family history of malignant hyperthermia. 3. History of acute lung injury or acute respiratory distress syndrome within 3 months before surgery. 4. Patients with cardiac insufficiency (NYHA grade ≥ 3), history of previous cerebral infarction, severe liver disease (such as liver failure) or chronic renal failure (glomerular filtration rate <30ml/min). 5. Pregnant, lactating women. 6. Surgery again. 7. Participate in other clinical trials.

研究实施时间:

Study execute time:

From 2019-05-22

To      1990-01-01

征募观察对象时间:

Recruiting time:

From 2019-05-22

To      1990-01-01

干预措施:

Interventions:

组别:

地氟烷组

样本量:

141

Group:

desflurane group

Sample size:

干预措施:

地氟烷维持麻醉

干预措施代码:

Intervention:

desflurane to maintain anesthesia

Intervention code:

组别:

丙泊酚组

样本量:

141

Group:

propofol group

Sample size:

干预措施:

丙泊酚维持麻醉

干预措施代码:

Intervention:

propofol to maintain anesthesia

Intervention code:

组别:

七氟烷组

样本量:

141

Group:

sevoflurane group

Sample size:

干预措施:

七氟烷维持麻醉

干预措施代码:

Intervention:

sevoflurane to maintain anesthesia

Intervention code:

样本总量 Total sample size : 423

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院

单位级别:

三级甲等

Institution/hospital:

West China Hospital, Sichuan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后全因死亡率

指标类型:

次要指标

Outcome:

Postoperative mortality

Type:

Secondary indicator

测量时间点:

术后住院期间和30天全因死亡率

测量方法:

Measure time point of outcome:

Postoperative hospitalization and 30-day all-cause mortality

Measure method:

指标中文名:

术后外科手术并发症分级

指标类型:

次要指标

Outcome:

Postoperative surgical complications classification

Type:

Secondary indicator

测量时间点:

术后7天

测量方法:

Measure time point of outcome:

7 days after surgery

Measure method:

指标中文名:

住院时间

指标类型:

次要指标

Outcome:

length of stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后肺部并发症分级

指标类型:

次要指标

Outcome:

Postoperative pulmonary grading

Type:

Secondary indicator

测量时间点:

术后7天

测量方法:

Measure time point of outcome:

7 days after surgery

Measure method:

指标中文名:

术后肺部并发症包括呼吸衰竭、肺部感染、胸腔积液、肺不张、气胸、支气管痉挛、吸入性肺炎、肺栓塞

指标类型:

主要指标

Outcome:

Postoperative pulmonary complications, include respiratory failure, respiratory infection, pleural effusion, atelectasis, pneumothorax, bronchospasm, aspiration pneumonitis, pulmonary embolism

Type:

Primary indicator

测量时间点:

术后7天

测量方法:

Measure time point of outcome:

7 days after surgery

Measure method:

指标中文名:

ICU停留时间

指标类型:

次要指标

Outcome:

ICU stay time

Type:

Secondary indicator

测量时间点:

术后

测量方法:

Measure time point of outcome:

postoperation

Measure method:

指标中文名:

恢复质量QoR-15

指标类型:

次要指标

Outcome:

Recovery quality QoR-15

Type:

Secondary indicator

测量时间点:

术后7天和30天

测量方法:

Measure time point of outcome:

7 days and 30 days after surgery

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 90
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由特定的研究员使用统计软件SPSS 22.0产生计算机随机序列对受试患者进行1:1:1的随机分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

All patients were assigned in a 1:1 ratio to one of the two groups, according to computer-generated randomization codes (SPSS 22.0) by a specific researcher.

盲法:

对受试患者、随访人员和统计人员设盲。

Blinding:

Blind method for subjects, follow-up staff and statisticians.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台.http://www.medresman.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Research Manager.http://www.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用病历记录表采集数据,临床试验公共管理平台(ResMan)管理数据。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record form to collect data; ResMan to manage data.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above